InsiderClue
Stocks · Health care · Surgical & Medical Instruments & Apparatus

Beta Bionics, Inc.

BBNX Clue Score57
United States Fiscal year ends December CIK 0001674632
$17.63 +1.15% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $17.63 −20.69% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 30 Jan 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Revenue12.0Operating income−35.9Net income−44.1EPS, diluted−8.31Fiscal year 2024Revenue65.1 +442.9%Operating income−45.3Net income−54.8EPS, diluted−8.60Fiscal year 2025Revenue100.3 +53.9%Operating income−71.7Net income−73.2EPS, diluted−1.81
FY2023FY2024FY2025
Revenue 12.0 65.1 100.3
Growth +442.9% +53.9%
Operating income −35.9 −45.3 −71.7
Net income −44.1 −54.8 −73.2
Growth
EPS, diluted −8.31 −8.60 −1.81

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2023Gross margin52.6%Operating margin−298.9%Net margin−367.6%Free cash flow margin−273.8%Fiscal year 2024Gross margin55.1%Operating margin−69.5%Net margin−84.1%Free cash flow margin−79.3%Fiscal year 2025Gross margin55.4%Operating margin−71.5%Net margin−73.0%Free cash flow margin−56.1%
FY2023FY2024FY2025
Gross margin 52.6% 55.1% 55.4%
Operating margin −298.9% −69.5% −71.5%
Net margin −367.6% −84.1% −73.0%
Free cash flow margin −273.8% −79.3% −56.1%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−32.4Capital expenditure−0.4Free cash flow−32.8Fiscal year 2024Operating cash flow−48.3Capital expenditure−3.4Free cash flow−51.7Fiscal year 2025Operating cash flow−50.9Capital expenditure−5.3Free cash flow−56.2
FY2023FY2024FY2025
Operating cash flow −32.4 −48.3 −50.9
Capital expenditure −0.4 −3.4 −5.3
Free cash flow −32.8 −51.7 −56.2
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash26.6Shareholders’ equity−203.1Fiscal year 2024Cash30.4Shareholders’ equity−245.4Fiscal year 2025Cash31.6Shareholders’ equity287.6
FY2023FY2024FY2025
Cash 26.6 30.4 31.6
Shareholders’ equity −203.1 −245.4 287.6

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
12.0 65.1 100.3
Growth +442.9% +53.9%
5.7 29.2 44.7
6.3 35.9 55.5
Growth +468.9% +54.8%
17.9 26.2 34.8
12.2 17.9 31.0
−35.9 −45.3 −71.7
Growth
n/a 0.0 0.0
−44.1 −54.8 −73.2
Growth
Per share
−8.31 −8.60 −1.81
−8.31 −8.60 −1.81
Growth
5.3 6.4 40.5
5.3 6.4 40.5
Growth +20.0% +536.7%

† The diluted share count jumps at 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 3 of 3 years on file.